Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis

Bo Liu; Nan Hu

doi:10.1007/s12672-025-04194-4

December 5, 2025Discover OncologyOpen Access

Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis

View Full Paper

Ask AI

Bookmark

Share

Key Points

Lidocaine inhibits cell proliferation in HER2-positive breast cancer.
The study reveals a novel mechanism targeting the OGT-CCNL1 axis.
Analysis demonstrates lidocaine's impact on cancer cell behavior.
Implications point to new treatment options for HER2-positive patients.

Implication

Observational analysis shows lidocaine reduces cell proliferation in HER2-positive breast cancer, suggesting a new therapeutic avenue.

Abstract

In conclusion, this study reveals a novel mechanism by which lidocaine inhibits HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis, highlighting a potential therapeutic avenue for HER2-positive breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/694022442d562116f28fbabe https://doi.org/10.1007/s12672-025-04194-4

View Full Paper

Ask AI

Bookmark

Share

Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis

Key Points

Implication

Abstract

Discussion

Cite This Study

Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading